- Kaminski,
R., Moriarty, T., Wolf, D., Culliton, D.,
Bodine, J., Davidson, M. and Davis, K.L. (1991). Famotidine, a histamine
H2 receptor antagonist and negative symptoms of schizophrenia. Biological
Psychiatry, 29, 67-68.
- Hirschowitz,
J., Hitzemann, R., Kaminski, R., Mann, M., Piscani, K., and Culliton,
D. (1993). D2 receptor occupancy and optimum antipsychotic
dose. APA Annual Meeting, San Francisco, May 22- 27. (Symposium).
- Kaminski,
R., Di Rocco, A., Molinari, S., Culliton,
D., Yahr, M. (1994). Treatment of bradyphrenia with famotidine,
a histamine H2 receptor antagonist. New Trends in Clinical Neuropharmacology,
Vol. VIII, Jan-Mar, 306. (Abstract presented at the 11th International
Symposium on Parkinson's Disease, Rome, Italy).
- Hirschowitz,
J., Hitzemann, R., Piscani, K., Burr, G., Frecska, E., Culliton,
D., Mann, M. & Curtis, C. (1997). The dose reduction in schizophrenia
(DORIS) study: A final report. Schizophrenia Research, 23, 31-43.
- Negrier, C. Fleury, R., Hoots, K., Gajek, H., Berg, R., Stephens, D., Tolenaar, D. (2008). Surgical interventions with FEIBA (SURF) - studying the feasibility of surgery in inhibitor patients. Abstract presented at WFH 2008 World Congress, Istanbul, Turkey.
- Negrier, C. Fleury, R., Ha Noh, J., Baghaei, F., Claeyssens, S., Yee, T., Gajek, H., Tolenaar, D., Stephens, D. (2009). The use of FEIBA during surgeries in hemophilia patients with inhibitors: update from SURF international registry. Abstract presented at ISTH 2009 World Congress, Boston, Massachusetts.
|